IONIQ Sciences recognized as “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021”
Salt Lake City, UT, December 14, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announces it has been awarded “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021” by Global 100. One of the critical innovations we believe that separates our IONIQ ProLung Test from other potential tests is in precisely what we are measuring. Using a novel application of bioimpedance technology, we believe we’re measuring the body’s systemic response to cancer. This enables earlier detection, and quite possibly detection of a wide array of cancers not tied to specific tumor types or sizes. Our ability to detect smaller 4-8mm pulmonary nodules in early cancer stages with greater accuracy than existing diagnostics is what earned us a ‘Breakthrough Device’ designation from the FDA.
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103